Works matching DE "IFOSFAMIDE"

Results: 375
    1

    Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 9, p. 5479, doi. 10.1007/s00432-022-04454-8
    By:
    • Rodriguez-Cid, Jeronimo Rafael;
    • Juarez-Vignon Whaley, Juan Jose;
    • Sánchez-Domínguez, Gisela;
    • Guzmán-Casta, Jordi;
    • Carrasco-CaraChards, Sonia;
    • Guzmán-Huesca, Jorge;
    • Riera-Sala, Rodrigo;
    • Sánchez-Ríos, Carla Paola;
    • Cruz-Zermeño, Mayte;
    • Seidman-Sorsby, Alec;
    • de Jesús Rodríguez-Zea, Ivan;
    • Alatorre-Alexander, Jorge Arturo;
    • Martínez-Barrera, Luis Manuel;
    • Santillán-Doherty, Patricio Javier;
    • Godina-Flores, Aminadab;
    • Imaz-Olguin, Victoria;
    • Sosa-Sánchez, Ricardo;
    • Green-Renner, Dan
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9

    Ifosfamide nephrotoxicity in adult patients.

    Published in:
    Clinical Kidney Journal, 2020, v. 13, n. 4, p. 660, doi. 10.1093/ckj/sfz183
    By:
    • Ensergueix, Gaël;
    • Pallet, Nicolas;
    • Joly, Dominique;
    • Levi, Charlène;
    • Chauvet, Sophie;
    • Trivin, Claire;
    • Augusto, Jean-Francois;
    • Boudet, Rémi;
    • Aboudagga, Hail;
    • Touchard, Guy;
    • Nochy, Dominique;
    • Essig, Marie;
    • Thervet, Eric;
    • Lazareth, Hélène;
    • Karras, Alexandre
    Publication type:
    Article
    10

    The growing pains of ifosfamide.

    Published in:
    Clinical Kidney Journal, 2020, v. 13, n. 4, p. 500, doi. 10.1093/ckj/sfaa017
    By:
    • Sprangers, Ben;
    • Lapman, Sebastian
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25

    A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.

    Published in:
    British Journal of Haematology, 2015, v. 170, n. 1, p. 118, doi. 10.1111/bjh.13388
    By:
    • Horton, Terzah M.;
    • Drachtman, Richard A.;
    • Chen, Lu;
    • Cole, Peter D.;
    • McCarten, Kathleen;
    • Voss, Stephan;
    • Guillerman, Robert P.;
    • Buxton, Allen;
    • Howard, Scott C.;
    • Hogan, Shirley M.;
    • Sheehan, Andrea M.;
    • López‐Terrada, Dolores;
    • Mrazek, Matthew D.;
    • Agrawal, Neeraj;
    • Wu, Meng‐Fen;
    • Liu, Hao;
    • De Alarcon, Pedro A.;
    • Trippet, Tanya M.;
    • Schwartz, Cindy L.
    Publication type:
    Article
    26
    27
    28
    29

    Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 437, doi. 10.1002/hon.3164_322
    By:
    • Fornecker, L.;
    • Delwail, V.;
    • Thieblemont, C.;
    • Ghesquieres, H.;
    • Bouabdallah, K.;
    • Tilly, H.;
    • Le Calloch, R.;
    • Morschhauser, F.;
    • Costello, R.;
    • Slama, B.;
    • Gyan, E.;
    • Chauchet, A.;
    • Ngirabacu, M.;
    • Durot, E.;
    • Choquet, S.;
    • Capdupuy, C.;
    • Le Goff, M.;
    • Voillat, L.;
    • Snauwaert, S.;
    • Amorim, S.
    Publication type:
    Article
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39

    Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.

    Published in:
    Oncologist, 2017, v. 22, n. 10, p. 1271, doi. 10.1634/theoncologist.2016-0464
    By:
    • Wagner, Michael J.;
    • Gopalakrishnan, Vancheswaran;
    • Ravi, Vinod;
    • Livingston, J. Andrew;
    • Conley, Anthony P.;
    • Araujo, Dejka;
    • Somaiah, Neeta;
    • Zarzour, Maria A.;
    • Ratan, Ravin;
    • Wang, Wei-Lien;
    • Patel, Shreyaskumar R.;
    • Lazar, Alexander;
    • Ludwig, Joseph A.;
    • Benjamin, Robert S.
    Publication type:
    Article
    40

    Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy.

    Published in:
    Oncologist, 2017, v. 22, n. 10, p. 1265, doi. 10.1634/theoncologist.2016-0463
    By:
    • Pretz, Jennifer L.;
    • Barysauskas, Constance M.;
    • George, Suzanne;
    • Hornick, Jason L.;
    • Raut, Chandrajit. P.;
    • Chen, Yen-Lin E.;
    • Marcus, Karen J.;
    • Choy, Edwin;
    • Hornicek, Francis;
    • Ready, John E.;
    • DeLaney, Thomas F.;
    • Baldini, Elizabeth H.
    Publication type:
    Article
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50

    Shrunken pore syndrome in childhood cancer survivors treated with potentially nephrotoxic therapy.

    Published in:
    Scandinavian Journal of Clinical & Laboratory Investigation, 2022, v. 82, n. 7/8, p. 541, doi. 10.1080/00365513.2022.2129437
    By:
    • Kooijmans, Esmee C. M.;
    • van der Pal, Helena J. H.;
    • Pilon, Maxime C. F.;
    • Pluijm, Saskia M. F.;
    • van der Heiden-van der Loo, Margriet;
    • Kremer, Leontien C. M.;
    • Bresters, Dorine;
    • van Dulmen-den Broeder, Eline;
    • van den Heuvel-Eibrink, Marry M.;
    • Loonen, Jacqueline J.;
    • Louwerens, Marloes;
    • Neggers, Sebastian J. C.;
    • van Santen, Hanneke M.;
    • Tissing, Wim J. E.;
    • de Vries, Andrica C. H.;
    • Kaspers, Gertjan J. L.;
    • Veening, Margreet A.;
    • Bökenkamp, Arend
    Publication type:
    Article